Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.25 USD
Change Today -0.07 / -0.96%
Volume 13.0K
ZSAN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 7:40 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

zosano pharma corp (ZSAN) Snapshot

Open
$7.47
Previous Close
$7.32
Day High
$7.47
Day Low
$7.01
52 Week High
01/27/15 - $12.40
52 Week Low
06/30/15 - $7.01
Market Cap
86.6M
Average Volume 10 Days
17.4K
EPS TTM
--
Shares Outstanding
11.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOSANO PHARMA CORP (ZSAN)

Related News

No related news articles were found.

zosano pharma corp (ZSAN) Related Businessweek News

No Related Businessweek News Found

zosano pharma corp (ZSAN) Details

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of various indications. The company’s lead product candidates include Daily ZP-PTH, a synthetic form of parathyroid hormone for treating severe osteoporosis, which has completed a Phase II trial; ZP-Glucagon, a hormone that raises blood glucose levels, intended for the emergency rescue of patients suffering from life-threatening, severe hypoglycemia, which is in Phase II clinical trial; and ZP-Triptan, a class of serotonin receptor agonists known as triptans, used for the treatment of migraine, which is in Phase I and II clinical trials. It has strategic partnership and license agreement with Eli Lilly and Company to develop ZP-PTH microneedle patch products; and Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.

26 Employees
Last Reported Date: 03/26/15
Founded in 2006

zosano pharma corp (ZSAN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.0K
Chief Medical Officer
Total Annual Compensation: $398.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $329.8K
Compensation as of Fiscal Year 2014.

zosano pharma corp (ZSAN) Key Developments

Zosano Pharma Corporation Secures $15.0 Million in Debt Financing Through Hercules Technology Growth Capital, Inc

Zosano Pharma Corporation announced that it has secured $15.0 million in debt financing through Hercules Technology Growth Capital Inc. Zosano amended its existing secured-term loan facility with Hercules to increase the total loan amount to $15.0 million, with an approximately $11.7 advance made to Zosano at closing of the loan amendment. Zosano Pharma has used approximately $11.4 million of the proceeds from this financing to prepay all amounts owing to BioMed Ventures under a 2012 promissory note, and will make interest-only payments to Hercules on the $15.0 million principal balance of the term loan on a monthly basis for twelve months beginning July 1, 2015 (or for 18 months if Zosano satisfies certain financing conditions), with repayment of the principal balance amortized in equal monthly installments of principal and interest after the interest-only period and through the loan's December 1, 2018 maturity date.

Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, its Microneedle Patch for Treatment of Severe Hypoglycemia

Zosano Pharma Corporation announced that it has completed enrollment in its Phase 2 clinical trial of ZP-Glucagon, a novel investigational patch treatment for severe hypoglycemia in diabetics. The trial was designed as a four-way cross-over study to investigate the safety and pharmacokinetics, as well as the efficacy to reverse insulin-induced hypoglycemia, of ZP-Glucagon versus intramuscular injections at two different dose levels. Adult participants diagnosed with type 1 diabetes were enrolled at two clinical sites.

Zosano Pharma Corporation Appoints Joseph 'Jay' P. Hagan to its Board of Directors

Zosano Pharma Corporation announced the election of Joseph 'Jay' P. Hagan to its board of directors, effective May 22, 2015. Mr. Hagan is Executive Vice President, Chief Business & Financial Officer of Orexigen Therapeutics Inc. Mr. Hagan has served as Orexigen's Chief Business & Financial Officer since 2011.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZSAN:US $7.25 USD -0.07

ZSAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $154.30 USD +0.35
Corium International Inc $13.69 USD -0.14
FUJIFILM Holdings Corp ¥4,454 JPY +80.50
View Industry Companies
 

Industry Analysis

ZSAN

Industry Average

Valuation ZSAN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.5x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOSANO PHARMA CORP, please visit www.zosanopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.